Replies to post #130049 on Biotech Values

[mouton29]

<<Yes - everyone fails the existing drugs at some point.>>

This was the argument an oncologist friend made to me in favor of Dendreon, contending that Zytiga is not really competition for Provenge -- after a time, patients will fail Zytiga. After all, hormone refractory is hormone refractory all the Zytiga does is defer the time till the patient is ready for Provenge. Therefore he thought Dendreon might be a buy in the 8.00's. I assume, though, that at some point, at least some patients are ready to give up or simply die first.